Clinical trial NCT05558878 - References

Diabetic Neuropathy Peripheral — Effect of Ambroxol in Diabetic Peripheral Neuropathy

Citation(s)

•   Albers JW, Pop-Busui R
  Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014 Aug;14(8):473. doi: 10.1007/s11910-014-0473-5. Review.
•   American Diabetes Association
  Standardized measures in diabetic neuropathy. Diabetes Care 1996;19(1S):72S-92S.
•   Ang L, Cowdin N, Mizokami-Stout K, Pop-Busui R
  Update on the Management of Diabetic Neuropathy. Diabetes Spectr. 2018 Aug;31(3):224-233. doi: 10.2337/ds18-0036.
•   Association, American Diabetes
  
•   Beeh KM, Beier J, Esperester A, Paul LD
  Antiinflammatory properties of ambroxol. Eur J Med Res. 2008 Dec 3;13(12):557-62. Review.
•   Boulton AJ, Malik RA, Arezzo JC, Sosenko JM
  Diabetic somatic neuropathies. Diabetes Care. 2004 Jun;27(6):1458-86. Review.
•   Boulton AJ, Malik RA
  Diabetic neuropathy. Med Clin North Am. 1998 Jul;82(4):909-29. Review.
•   Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association
  Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005 Apr;28(4):956-62. Review.
•   Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD
  Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications. 2007 Sep-Oct;21(5):306-14.
•   Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, Feldman EL, Litchy WJ, O'Brien PC, Russell JW; Toronto Expert Panel on Diabetic Neuropathy
  Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011 Oct;27(7):620-8. doi: 10.1002/dmrr.1226. Review.
•   Elmarakby AA, Sullivan JC
  Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012 Feb;30(1):49-59. doi: 10.1111/j.1755-5922.2010.00218.x. Epub 2010 Aug 16. Review.
•   Gaida W, Klinder K, Arndt K, Weiser T
  Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology. 2005 Dec;49(8):1220-7. Epub 2005 Sep 21.
•   Ganesh Yerra V, Negi G, Sharma SS, Kumar A
  Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-?B pathways in diabetic neuropathy. Redox Biol. 2013 Aug 1;1:394-7. doi: 10.1016/j.redox.2013.07.005. Review.
•   Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, Burt V, Curtin L, Engelgau M, Geiss L; 1999-2000 national health and nutrition examination survey
  Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care. 2004 Jul;27(7):1591-7.
•   Heidari N, Sajedi F, Mohammadi Y, Mirjalili M, Mehrpooya M
  Ameliorative Effects Of N-Acetylcysteine As Adjunct Therapy On Symptoms Of Painful Diabetic Neuropathy. J Pain Res. 2019 Nov 19;12:3147-3159. doi: 10.2147/JPR.S228255. eCollection 2019.
•   Kasznicki J, Kosmalski M, Sliwinska A, Mrowicka M, Stanczyk M, Majsterek I, Drzewoski J
  Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep. 2012 Sep;39(9):8669-78. doi: 10.1007/s11033-012-1722-9. Epub 2012 Jun 21.
•   Kern KU, Weiser T
  Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation. Schmerz. 2015 Dec;29 Suppl 3:S89-96. doi: 10.1007/s00482-015-0060-y.
•   Mullin S, Smith L, Lee K, D'Souza G, Woodgate P, Elflein J, Hällqvist J, Toffoli M, Streeter A, Hosking J, Heywood WE, Khengar R, Campbell P, Hehir J, Cable S, Mills K, Zetterberg H, Limousin P, Libri V, Foltynie T, Schapira AHV
  Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol. 2020 Apr 1;77(4):427-434. doi: 10.1001/jamaneurol.2019.4611.
•   Narita A, Shirai K, Itamura S, Matsuda A, Ishihara A, Matsushita K, Fukuda C, Kubota N, Takayama R, Shigematsu H, Hayashi A, Kumada T, Yuge K, Watanabe Y, Kosugi S, Nishida H, Kimura Y, Endo Y, Higaki K, Nanba E, Nishimura Y, Tamasaki A, Togawa M, Saito Y, Maegaki Y, Ohno K, Suzuki Y
  Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study. Ann Clin Transl Neurol. 2016 Feb 2;3(3):200-15. doi: 10.1002/acn3.292. eCollection 2016 Mar.
•   Pang L, Lian X, Liu H, Zhang Y, Li Q, Cai Y, Ma H, Yu X
  Understanding Diabetic Neuropathy: Focus on Oxidative Stress. Oxid Med Cell Longev. 2020 Jul 31;2020:9524635. doi: 10.1155/2020/9524635. eCollection 2020. Review.
•   Pawlinski L, Krawczyk M, Fiema M, Tobor E, Kiec-Wilk B
  Dual-action ambroxol in treatment of chronic pain in Gaucher Disease. Eur J Pain. 2020 May;24(5):992-996. doi: 10.1002/ejp.1538. Epub 2020 Mar 9.
•   Püschmann S, Engelhorn R
  [Pharmacological study on the bromhexine metabolite ambroxol (author's transl)]. Arzneimittelforschung. 1978;28(5a):889-98. German.
•   Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee
  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10.
•   Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A
  Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol. 2014;2014:674987. doi: 10.1155/2014/674987. Epub 2014 Apr 30. Review.
•   Schutz A, Gund HJ, Pschorn U, Aicher B, Peil H, Müller A, de Mey C, Gillissen A
  Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept. Arzneimittelforschung. 2002;52(3):194-9.
•   Sheikh, W
  M. E., Alahmar, I. E., Salem, G. M., & El-Sheikh, M. A. (2019). Tumor necrosis factor alpha in peripheral neuropathy in type 2 diabetes mellitus. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 55(1), 1-7. https://doi.org/10.1186/s41983-019-0080-0
•   Soliman E,Gellido C
  Diabetic Neuropathy. eMedicine.com March 29, 2002.
•   Su X, Wang L, Song Y, Bai C
  Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive Care Med. 2004 Jan;30(1):133-40. Epub 2003 Sep 20.
•   Sunkari S, Thatikonda S, Pooladanda V, Challa VS, Godugu C
  Protective effects of ambroxol in psoriasis like skin inflammation: Exploration of possible mechanisms. Int Immunopharmacol. 2019 Jun;71:301-312. doi: 10.1016/j.intimp.2019.03.035. Epub 2019 Mar 29.
•   Thomas PK
  Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 1997 Sep;46 Suppl 2:S54-7. Review.
•   Vallianou N, Evangelopoulos A, Koutalas P
  Alpha-lipoic Acid and diabetic neuropathy. Rev Diabet Stud. 2009 Winter;6(4):230-6. doi: 10.1900/RDS.2009.6.230. Epub 2009 Dec 30.
•   Weiser T (2000) The secretolytic ambroxol blocks neuronal Na+channels
  Soc Neurosci Abstr 454.14.
•   Weiser T, Wilson N
  Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol. Mol Pharmacol. 2002 Sep;62(3):433-8.
•   Weiser T
  Comparison of the effects of four Na+ channel analgesics on TTX-resistant Na+ currents in rat sensory neurons and recombinant Nav1.2 channels. Neurosci Lett. 2006 Mar 13;395(3):179-84. Epub 2005 Nov 15.
•   Xia DH, Xi L, Xv C, Mao WD, Shen WS, Shu ZQ, Yang HZ, Dai M
  The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor beta1 and tumor necrosis factor alpha. Med Oncol. 2010 Sep;27(3):697-701. doi: 10.1007/s12032-009-9271-3. Epub 2009 Jul 28.

Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy

Details for clinical trial NCT05558878